1. Academic Validation
  2. POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway

POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway

  • Biochem Biophys Res Commun. 2020 Dec 10;533(3):533-539. doi: 10.1016/j.bbrc.2020.09.003.
Di Wu 1 Hong-Yao Jia 1 Na Wei 2 Si-Jie Li 3
Affiliations

Affiliations

  • 1 Department of Breast Surgery, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China.
  • 2 The First Operating Room, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China.
  • 3 Department of Breast Surgery, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China. Electronic address: [email protected].
Abstract

Over-expression of the human epidermal growth factor receptor-2 (HER2) is related to aggressive tumors and poor prognosis in breast Cancer. Trastuzumab (TRA) resistance leads to tumor recurrence and metastasis, resulting in poor prognosis in HER2-positive breast Cancer. POU Class 4 Homeobox 1 (POU4F1) is a member of the POU domain family transcription factors, and has a key role in regulating cancers. However, its effects on TRA-resistant HER2-positive breast Cancer are still vague. In the present study, we found that POU4F1 expression was dramatically increased in clinical breast Cancer specimens with TRA resistance. Higher POU4F1 was also detected in HER2-positive breast Cancer cells with TRA resistance than that of the parental ones. Poor prognosis was detected in breast Cancer patients with high POU4F1 expression. Under TRA treatment, POU4F1 knockdown significantly reduced the proliferative capacity of HER2-positive breast Cancer cells with TRA resistance. POU4F1 silence also sensitized resistant HER-positive breast Cancer cells to TRA treatment in vivo using a xenograft mouse model, along with the markedly reduced tumor growth rate and tumor weight. Moreover, we found that POU4F1 deletion greatly decreased the activation of mitogen-activated or extracellular signal-regulated protein kinase kinases 1 and 2 (MEK1/2) and extracellular-regulated kinase 1/2 (ERK1/2) signaling pathways in breast Cancer cells with TRA resistance. Migration and invasion were also effectively hindered by POU4F1 knockdown in TRA-resistant HER2-positive breast Cancer cells. Notably, we found that POU4F1 deletion-improved chemosensitivity of HER2-positive breast Cancer cells with drug-resistance to TRA treatment was closely associated with the blockage of ERK1/2 signaling. Collectively, our findings reported a critical role of POU4F1 in regulating TRA resistance, and demonstrated the underlying molecular mechanisms in HER2-positive breast Cancer. Thus, POU4F1 may be a promising prognostic and therapeutic target to develop effective treatment for overcoming TRA resistance.

Keywords

Breast cancer; ERK1/2; Migration and invasion; POU4F1; Trastuzumab resistance.

Figures
Products